GUERBET Vendor's profile
FDA Approves Lipiodol® Injection for Imaging of Tumors in Adults with Known Hepatocellular Carcinoma
Donnerstag, 10. April 2014
FDA Approves Lipiodol® (Ethiodized Oil) Injection for Imaging of Tumors in Adults with Known Hepatocellular Carcinoma (HCC) Princeton (NJ), Guerbet, a pioneer in the field of contrast agents for medical imaging announced that Lipiodol® was approved by the US Food and Drug Administration purs...
Guerbet LLC to Showcase Contrast Agent Dotarem® at RSNA Annual Meeting December 1 - 6 in Chicago
Dienstag, 26. November 2013
Princeton, NJ – Guerbet announced today that it will have the company’s largest exhibit presence ever at the Radiology Society of North America (RSNA)’s 99th Assembly and Annual Meeting Dec. 1-6 in Chicago. Guerbet will be exhibiting at Booth #2535 South Building, Hall A. This will mark the...
Dotarem® (gadoterate meglumine) Injection Now Offered Via Novation
Dienstag, 12. November 2013
Villepinte, 12 November 2013 Guerbet LLC (USA) announced that Novation, the leading healthcare supply chain expertise, analytics and contracting company in the US, has awarded a new agreement for Dotarem® (gadoterate meglumine) Injection. Dotarem® is a gadolinium-based contrast age...
To feature here : Get in touch
Ensuring performance of x-Ray equipment: a holistic approach
Patient-Specific Radiation Dose Estimation in Breast Cancer Screening
Increasing interventional radiology capacity while reducing patient radiation
A healthy dose of radiation monitoring
The first fully digital C-arm